Analysts have clear opinions on ALEC.

Alector, Inc. (ALEC) is followed by analysts on the street. Their average price target to be reached in the next 12 months has a
Yaron Werber from Cowen & Co. rates it a Buy with a target of —.

Similarly, 8 months ago Geoff Meacham of Merrill Lynch Reiterated a Buy with a target of $27.00.

The consensus on the street is Moderate Buy.

What does Alector, Inc.(ALEC) do ?
Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer’s disease, and Parkinson’s disease. The company was founded b

Alector, Inc.(ALEC) Insider Trades

Multiple company employees have indulged in significant insider trading. Alector, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that:

Chief Medical Officer, Paul Robert : S – Sale(-$146,800) of ALEC in the trading session of 2019-10-15.

Chief Business Officer Oney Sabah : S – Sale+OE(-$8,000) of ALEC in the trading session of 2019-09-20.

Chief Medical Officer Paul Robert : S – Sale+OE(-$80,000) of Alector, Inc. in the trading session of 2019-09-20.